Pharmaceutical Lobbying: By the Numbers

Why Pharma Spends More Than Anyone

Healthcare regulation directly impacts pharmaceutical company revenues in ways few other industries experience. Drug pricing legislation, FDA approval processes, Medicare/Medicaid reimbursement rates, patent protections, and import regulations all have multi-billion-dollar implications for drug makers.

The Pharmaceutical Research & Manufacturers of America (PhRMA), the industry's main trade association, alone spends over $27 million annually on lobbying — making it one of the single biggest lobbying entities in the entire country. But PhRMA is just the tip of the iceberg.

Top Pharmaceutical Lobbying Spenders

What Pharma Lobbies On

Using the LDA issue code system, pharmaceutical lobbying filings primarily fall under:

• PHA (Pharmacy): Drug pricing, prescription costs, pharmacy benefit managers (PBMs)
• HCR (Healthcare): Medicare, Medicaid, ACA provisions, insurance coverage requirements
• BUD (Budget/Appropriations): NIH funding, FDA budget, research grants
• MED (Medical Research): Clinical trials, rare diseases, research funding
• TRD (Trade): Drug importation, international trade agreements, IP protections

The Drug Pricing Battle

The single biggest lobbying issue for pharmaceutical companies has been drug pricing reform. When Congress considers legislation to allow Medicare to negotiate drug prices, cap insulin costs, or enable drug importation from Canada, pharmaceutical lobbying spending surges dramatically.

The Inflation Reduction Act of 2022, which allowed Medicare to negotiate prices on some drugs for the first time, triggered one of the most intense lobbying campaigns in recent history. Our data shows significant spending spikes in the quarters surrounding the bill's passage.

Pharma's Revolving Door

The pharmaceutical industry is one of the heaviest users of the revolving door. Former FDA officials, HHS staffers, and congressional health committee aides frequently move to lobbying roles at drug companies and trade associations. Our data tracks these movements across the industry — see the full revolving door analysis.

Explore the Data Yourself

All of the data behind this analysis is available on OpenLobby. Search for any pharmaceutical company, view their lobbying filings quarter by quarter, see which lobbyists work for them, and track their spending over time.

The Insulin Lobbying Battle

Few issues illustrate pharmaceutical lobbying dynamics better than insulin pricing. The three companies that control the U.S. insulin market — Eli Lilly, Novo Nordisk, and Sanofi — spent millions lobbying as Congress considered insulin price caps. Their arguments centered on the complexity of drug pricing, the role of PBMs in inflating list prices, and the risk that price caps would reduce innovation.

Patient advocacy groups pushed back with their own lobbying campaigns, funded by concerned citizens and healthcare organizations. The result was a compromise: insulin copay caps for Medicare beneficiaries, but no broader price controls. Both sides claimed victory, and lobbying continues on implementation details.

This pattern repeats across pharmaceutical policy: intense lobbying from both industry and patient advocates, with outcomes often reflecting the side with greater resources and insider access. Our data shows that pharmaceutical companies and their trade associations consistently outspend patient advocacy groups by ratios of 100:1 or more.

FDA Approval and Regulatory Lobbying

Beyond drug pricing, pharmaceutical lobbying heavily focuses on FDA regulation. Companies lobby on approval timelines, clinical trial requirements, post-market surveillance, and drug classification decisions. Faster approvals mean earlier revenue; more flexible trial requirements mean lower development costs; and favorable classifications (prescription vs. over-the-counter, controlled vs. non-controlled) have enormous market implications.

PhRMA and individual companies maintain continuous engagement with the FDA and Congress on regulatory issues, arguing that overly strict requirements stifle innovation while critics counter that weakened standards compromise patient safety. Track FDA-related lobbying through the MED (Medical Research) and PHA (Pharmacy) issue codes in our issue explorer.

Pharmacy Benefit Managers (PBMs): The Hidden Lobbying War

One of the most intense lobbying battles in healthcare involves Pharmacy Benefit Managers — the middlemen that negotiate drug prices between manufacturers, insurers, and pharmacies. The three largest PBMs (CVS Caremark, Express Scripts/Cigna, and OptumRx/UnitedHealth) control over 80% of the market and spend millions lobbying to protect their business model.

Drug manufacturers lobby to rein in PBM power, arguing that PBMs pocket rebates that should flow to patients. PBMs counter that they negotiate lower prices. Congress has considered bipartisan PBM reform legislation, driving lobbying from both sides. This fight plays out primarily under the PHA (Pharmacy) and HCR (Healthcare) issue codes in our data.

Biosimilars and Patent Thickets

A growing share of pharmaceutical lobbying focuses on the biological drug market. Brand-name biologic manufacturers lobby to extend patent protections through "patent thickets" — clusters of dozens of patents around a single drug that delay biosimilar competition. Biosimilar manufacturers lobby for faster FDA approval pathways and against patent gaming strategies.

With blockbuster biologics like Humira ($21B+ in annual sales at peak) facing biosimilar competition, the financial stakes are enormous. AbbVie alone has spent millions lobbying to protect its Humira patent portfolio, making it one of the most visible examples of patent-focused lobbying.

The 2026 Pharmaceutical Lobbying Outlook

The pharmaceutical lobbying landscape in 2026 is dominated by several key battles: implementation of the Inflation Reduction Act's drug pricing provisions, potential expansion of Medicare price negotiations to more drugs, proposed legislation on PBM transparency, and ongoing debates about FDA approval standards for AI-assisted drug development.

With mid-term elections approaching, pharmaceutical lobbying is expected to intensify as companies seek to shape the next Congress's healthcare agenda. Track real-time shifts on our momentum page.